Verrica Pharmaceuticals Inc. (VRCA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Verrica Pharmaceuticals Inc. reported revenue of $35.58M, up 370.2% from the prior year. The company ran a net loss, with a net margin of -50.3%. It held $47.13M in total assets against $22.39M in total liabilities.
Key ratios (FY2025)
-34.2%
Operating margin
-50.3%
Net margin
-72.3%
Return on equity
+370.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.58M | $7.57M | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | $2.60M | $500.0K | — | — | — | — | — | — | — |
| Operating Income | -$12.19M | -$65.92M | -$65.76M | -$21.30M | -$30.91M | -$40.18M | -$30.08M | -$21.88M | -$4.46M | — |
| Net Income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | -$35.08M | -$42.69M | -$28.21M | -$20.65M | -$4.46M | — |
| EPS (Diluted) | $-1.68 | $-14.78 | $-1.48 | $-0.72 | $-1.30 | — | — | — | — | — |
| Total Assets | $47.13M | $54.13M | $81.60M | $44.72M | $80.12M | $74.15M | $68.42M | $91.91M | $9.08M | — |
| Total Liabilities | $22.39M | $63.99M | $61.83M | $4.69M | $47.52M | $41.17M | $3.41M | $2.48M | $616.0K | — |
| Shareholders' Equity | $24.74M | -$9.86M | $19.76M | $40.03M | $32.60M | $32.99M | $65.02M | $89.43M | -$7.04M | -$2.66M |
| Cash & Equivalents | $30.15M | $46.33M | $69.55M | $34.27M | $15.75M | $10.69M | $9.24M | $10.27M | $8.66M | $527.0K |
| Operating Cash Flow | -$17.63M | -$60.93M | -$38.58M | -$18.65M | -$27.58M | -$30.21M | -$27.41M | -$17.87M | -$4.58M | — |
| Capital Expenditures | $0 | $27.0K | $362.0K | $302.0K | $883.0K | $1.47M | $682.0K | $774.0K | — | — |
| Shares Outstanding | 17.18M | 9.18M | 42.41M | 41.09M | 27.52M | 25.44M | 25.79M | 25.70M | 3.70M | — |